Lorena Păduraru

University of Oradea

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Mihaela Simona Popoviciu

University of Oradea

Simona Cavalu

University of Oradea

Galal Yahya

Zagazig University

Roxana Adriana Stoica

Carol Davila University of Medicine and Pharmacy

Kamel Metwally

University of Tabuk

Dana Carmen Zaha

University of Oradea

Mominur Rahman

Daffodil International University

Claudiu Teodorescu

Carol Davila University of Medicine and Pharmacy

Delia Reurean‐Pintilei

Victor Babeș University of Medicine and Pharmacy Timișoara

Raluca Marinela Nutas

Cooperative Institutions

University of Oradea

Carol Davila University of Medicine and Pharmacy

Morpho (United States)

Amita Health St. Mary's Hospital

Zagazig University

Daffodil International University

Hai phong University Of Medicine and Pharmacy

National Institute of Diabetes and Digestive and Kidney Diseases

Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș

Victor Babeș University of Medicine and Pharmacy Timișoara

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Aetiology of Bacterial Infections and Antibiotic Resistance in Pediatric Patients from a Romanian Hospital

Pharmacophore (2022)

Lorena Păduraru Alexandru Daniel Jurcă Dana Carmen Zaha Florica Ramona Dorobanțu Mădălin Alexandru Hasan

The development of microorganism resistance to antibiotics is a topic of global interest and Romania is among the most vulnerable countries in terms of antimicrobial resistance. Our retrospective study was carried out for a year at the Emergency Clinical Hospital for Children "Saint John" in Galati, on a number of 9910 pathological samples. The main isolated strains were Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae. A percent of 25.4 was methicillin-resistant Stap

Etiology

Romanian

10.51847/r2feu5ajxs

Cite

Citations (4)

Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities

International Journal of Molecular Sciences (2023)

Mihaela Simona Popoviciu Lorena Păduraru Raluca Marinela Nutas Alexandra Maria Ujoc Galal Yahya

Secondary diabetes mellitus is frequently ignored in specialized literature. In this narrative review, the main endocrinopathies accompanied by increased glycemic values are identified, as well as the mechanisms by which the excess or deficiency of certain hormones impact beta cell function or insulin resistance. The main endocrinopathies (acromegaly, Cushing’s syndrome, Basedow–Graves’ disease, pheochromocytoma, somatostatinoma and glucagonoma) and their characteristics are described along with the impact of hormone changes on blood sugar, body mass index and other parameters associated with diabetes. The overall information regarding the complex molecular mechanisms that cause the risk of secondary diabetes and metabolic syndrome is of crucial importance in order to prevent the development of the disease and its complications and particularly to reduce the cardiovascular risk of these patients. The purpose of this study is to highlight the particular features of endocrine pathologies accompanied by an increased risk of developing diabetes, in the context of personalized therapeutic decision making. The epidemiological, physiopathological, clinical and therapeutic approaches are presented along with the importance of screening for diabetes in endocrine diseases.

Endocrine disease

10.3390/ijms241612676

Cite

Citations (24)

The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review

Journal of Mind and Medical Sciences (2024)

Mihaela Simona Popoviciu Lorena Păduraru Mominur Rahman Fatema Akter Supti Roxana Adriana Stoica

Worldwide, metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant public health concern, especially since more than fifty percent of people with type 2 diabetes are affected by it. This pathological condition includes all states of fatty liver disease, from non-alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH). Prolonged evolutions can lead to cirrhosis and cancer, so treatment must be started early. Hepatic steatosis may be improved by sodium glucose co-transporter 2 inhibitors (SGLT2 inhibitors), which prevent glucose reabsorption in the proximal renal tubule and increase urinary excretion, thus lowering plasma glucose levels. Experimental studies in animal models have suggested that SGLT2 inhibitors may have beneficial modulatory effects on NAFLD and NASH, while numerous clinical trials have demonstrated their favorable effects on the liver enzymes, body mass index, blood lipids, blood glucose, and insulin resistance in NAFLD patients. This review highlights the state of knowledge regarding the epidemiology, diagnosis and pathogenetic pathways of MAFLD, focusing primarily on the effectiveness of SGLT2 inhibitors as a promising drug class in the treatment of NAFLD.

Narrative review

10.22543/2392-7674.1439

Cite

Citations (0)

Prevalence of comorbidities and survival analysis of COVID-19 patients – an observational study from a tertiary healthcare center in North West Romania

Journal of Mind and Medical Sciences (2023)

Mihaela Simona Popoviciu Lorena Păduraru Roxana Adriana Stoica Anca Pantea Stoian Claudiu Teodorescu

Objectives. The experience accumulated in the last two years shows that the prevention of COVID-19 in people with comorbidities (protective measures, vaccination, etc.) still remains a public health priority. In this context, the aim of our study was to perform a retrospective, observational study in order to assess the time-to-death and risk factors of mortality among COVID-19 patients. Materials and Methods. The study was conducted on 177 patients admitted to Oradea Emergency County Hospital, Bihor, Romania, between October and December 2021. Inclusion criteria were patients over 18 years positive for COVID-19 in upper respiratory tract samples using real-time PCR test. Exclusion criteria were pregnant women, ageyears, and patients with incomplete records at admission. Results. The mortality rate was assessed in correlation with the most prevalent comorbidities such as diabetes, cardiovascular diseases, hypertension, chronic kidney disease, and chronic pulmonary diseases, either alone or associated. During hospitalization, an aggravated health condition was noticed for 71 patients (40.11%). Among them, 47 patients were transferred to the intensive care unit (66.20%) due to severe respiratory failure, aggravation of associated diabetes and/or other associated comorbidities. Ventilation support was necessary in 122 cases (68.63%). The average survival time was 8.66 days. In conclusion, we found that the most prevalent comorbidities were cardiovascular diseases, being the major risk factor for mortality or aggravation after hospitalization. Its association with diabetes caused a risk of death 2.1 times higher than in patients without comorbidities. Based on Kaplan–Meier survival analysis, we found that the in-hospital survival rate was significantly higher in females compared to males (50.52% vs 33.75%).

10.22543/2392-7674.1401

Cite

Citations (0)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials

International Journal of Molecular Sciences (2023)

Mihaela-Simona Popoviciu Lorena Păduraru Galal Yahya Kamel Metwally Simona Cavalu

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio–metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.

Depression

10.3390/ijms241310449

Cite

Citations (92)